JNJ Johnson & Johnson

$-1.92 (-1.29%)

JNJ Stock Analysis Overview

What this means: Johnson & Johnson (JNJ) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 77 means that our comprehensive methodology rates Johnson & Johnson above 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full JNJ report

Johnson & Johnson (JNJ) Analyst Forecast

Next 12 months ➝Current Price$146.7352-week High$157.0052-week Low$109.16MEAN$165.31+12.66%HIGH$182.00+24.04%LOW$150.00+2.23%
  • Last Price$146.73
  • Previous Close$148.65
  • Change $-1.92
  • Open$146.80
  • Volume8,149,598
  • Avg. Volume (100-day)10,034,882
  • Market Capitalization$387B
  • Days Range $145.58 - $148.37
  • 52-week Range $109.16 - $157.00
  • Dividend Yield2.72%
  • Ex. Dividend Date05/22/2020
  • P-E23.1
  • EPS6.41
  • Earnings Date07/21/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta0.222
  • PEG Ratio3.20
  • Volatility0.22
  • Average True Range0.03
Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.